Progress and introduction
of main products
Multi-Pathway Blockade:(1)TL1A: Reduces pro-inflammatory signaling (2)IL-23 p19: Lowers Th17 cell activation and IL-17 production (3)α4β7: Limits lymphocyte migration to the gut
Synergistic Effect: Combined inhibition offers broader anti-inflammatory benefits
Optimized Pharmacokinetics: Extended half-life enables less frequent dosing
Enhanced Safety: Advanced design minimizes immune complex formation, low pre-existing antibodies and ADA
Good Druggability: High yeild and high concentration feasibility
TL1A/DR3 Inhibition: Reduces IFNγ release and dampens inflammation
IL-23/IL-23R Blockade: Inhibits Th17 cell differentiation, lowering IL-17 levels
α4β7 Inhibition: Reduces gut-directed lymphocyte trafficking
These combined actions work together to achieve effective immune modulation in IBD
IBD– Crohn’s Disease, Ulcerative Colitis
Route: Sc. injection.
Pharmacokinetics: Engineered Fc, designed for 2–3× longer half-life than conventional antibodies, allowing for reduced dosing frequency
